The session will explore a variety of strategies in drug development, including small molecules, antibodies, and antisense oligonucleotides. Experts will discuss the targeting of crucial pathological features like amyloid plaques and tau tangles, along with emerging approaches focusing on neuroinflammation, synaptic dysfunction, and neuroprotective mechanisms.
A significant aspect of the session will concentrate on the design and execution of clinical trials, emphasizing the necessity for creative approaches to surmount obstacles that have hindered previous drug development endeavors in dementia. Researchers will share their insights on optimizing patient selection, utilizing biomarkers, and integrating cognitive and functional endpoints to evaluate treatment effectiveness.
The scientific session on drug development for dementia aims to provide a comprehensive overview of the current landscape in the field, emphasizing the potential of innovative therapeutic approaches and addressing challenges that must be tackled to translate scientific advancements into effective treatments for patients.
